Hansoh Pharmaceutical: One Molecule, One Royalty Book, and a Price That Already Pays for Both

† 2023-2025 innovative-product sales are derived by subtracting disclosed collaboration revenue from “innovative medicines and collaborative products”; mature sales are then the residual of product sales. 2021-2022 innovative sales were separately disclosed. Minor differences reflect rounding. Sources: Hansoh filings.

This bridge changes the investment argument. Recurring product sales compounded only about 7.4% from 2021 through 2025 because a 24.9% compound increase in innovative products had to overcome a 16.5% annual decline in mature drugs. In 2025, the crossover became decisive: innovative products added roughly RMB2.33bn of revenue year on year while mature products lost only about RMB0.11bn. Innovative growth is now genuinely outrunning legacy erosion rather than merely hiding it in a blended number.

Aumolertinib is the concentration risk inside that success. Hansoh does not disclose molecule-level revenue, but a 2026 Chinese industry report estimated 2025 aumolertinib sales at RMB5.53bn, making it the largest-selling domestically developed innovative drug in the Chinese market on that estimate. If the figure is directionally correct, aumolertinib represented about 37% of Hansoh's total FY2025 revenue and 54% of my derived innovative-product sales. Because the company does not disclose molecule-level gross profit, any precise claim that it supplies a specified percentage of group earnings would be false precision; my valuation stress tests assume roughly 40–50% of normalized domestic commercial earnings is economically tied to the molecule.

Its competitive field is formidable. AstraZeneca's osimertinib established the third-generation EGFR-TKI class globally, while furmonertinib and other Chinese entrants created an increasingly crowded domestic market. The important development is that Hansoh has continued extending aumolertinib's label rather than relying on a single metastatic setting. That increases duration, but it does not remove class competition, NRDL price pressure or eventual patent risk. I could not verify from a current primary source a reliable nationwide 2026 market-share series, a clean dose-adjusted NRDL price comparison with osimertinib, or a complete patent-expiry schedule; I therefore do not manufacture those figures.

The February 2026 European approval is strategically useful but financially less important today than the headline suggests. The European Commission approved Aumseqa, the ex-China brand for aumolertinib, for first-line common EGFR-mutated advanced NSCLC and T790M-positive advanced disease. Yet Hansoh has not disclosed a European commercial infrastructure comparable with AstraZeneca's, and the December 2025 Glenmark agreement covers numerous emerging markets, Australia, New Zealand and Russia/CIS rather than Europe. Until Hansoh announces either a European commercialization partner, launch economics or meaningful sales, I value the EU approval primarily as regulatory validation and future partnering optionality.

The ADC story has meanwhile become stronger than it was when the GSK deals were signed. HS-20093 obtained FDA Breakthrough Therapy designation and EMA PRIME support under GSK's development programme. In China, where Hansoh retained rights, the ARTEMIS-008 Phase III trial met its overall-survival endpoint in small-cell lung cancer in July 2026 and ARTEMIS-011 met its independent-review PFS endpoint in osteosarcoma on 2026-07-28. Hansoh said it would engage China's CDE in preparation for a BLA following the osteosarcoma readout. These events raise the probability that the GSK agreement ultimately generates royalties and milestones, but probability is not cash.

That distinction is especially important because Chinese biotechnology licensing has become one of the market's dominant narratives. Reuters reported that aggregate Chinese out-licensing headline deal value reached a record US$137.7bn in 2025; another report cited approximately US$110bn in the first half of 2026. Patent cliffs and pressure on Western pharmaceutical R&D productivity have made China a hunting ground for comparatively advanced, comparatively inexpensive clinical assets. Hansoh is a direct beneficiary. It is also being valued in a market where headline “deal value” has become an easy source of exaggeration, because most of those billions consist of milestones that may never become payable.

The balance sheet adds a second source of confusion. FY2025 cash and bank balances were RMB31.55bn, of which RMB28.14bn consisted of deposits longer than three months. Those deposits earned 1.35%–4.50%, and bank interest income alone reached RMB1.08bn in 2025. The cash balance was more than twice annual revenue and over nine times annual R&D. Yet the company simultaneously raised approximately HK$3.90bn net through an August 2025 placement at HK$36.30 and another roughly HK$4.64bn net through zero-coupon 2033 convertible bonds in February 2026. The new bond converts initially at HK$57.39 and would add about 81.5m shares, roughly 1.3% dilution, if fully converted.

Cash is therefore a capital-allocation question before it is a valuation cushion. Management says new capital is intended largely for R&D, in-licensing, new facilities and the Shanghai global R&D headquarters, with the 2026 bond proceeds expected to be deployed through 2031. That is coherent with an attempt to scale a multi-modality innovation platform. Raising fresh capital while RMB31.5bn already sat on the balance sheet nevertheless places a heavy burden of proof on future R&D returns.

The current market price embodies the hybrid nature of the company. At HK$33.34, Hansoh's equity value is approximately HK$202.2bn. FY2025 EPS of RMB0.93 translates to roughly HK$1.08 at the 2026-08-14 exchange rate, giving a headline P/E near 31 times. Deducting FY2025 cash reduces enterprise value to about HK$165.5bn, but removing the after-tax contribution of RMB1.08bn of interest income from earnings brings the cash-adjusted operating multiple back to roughly 31 times. In other words, the huge cash balance does not secretly make the operating business cheap; its interest income is already supporting reported earnings.

The share price itself captures the narrative shift. Hansoh listed in June 2019 with a maximum/final offer price around HK$14.26 and raised roughly US$1bn. The stock subsequently enjoyed the 2020-2021 Chinese healthcare rerating, then suffered as centralized procurement, reimbursement pressure and the broader Chinese growth-stock derating collided with its legacy exposure. Licensing from 2023 onward gave investors a new framework: Hansoh could be valued not simply as a China branded-pharma company but as a source of assets for Western pharma. At HK$33.34, the stock is still more than twice the IPO price but about 25% below the recent 52-week high of HK$44.22. The January 2026 convertible-bond announcement itself triggered a roughly 5% one-day decline, showing that investors are sensitive to dilution and capital accumulation even while rewarding the pipeline.

My qualitative portrait is company in transition. The generics-to-innovative transition is already economically visible; the next transition, from Chinese commercial drugmaker to repeatable global discovery-and-royalty platform, is not yet fully proven. Hansoh has shown that Western companies will repeatedly pay real upfront cash for its science. It has not yet shown that those transactions will produce a durable stream of late-stage milestones and royalties large enough to justify valuing the pipeline like a global biotechnology platform.

The main bull/bear disagreement follows directly. Bulls see the RMB10.24bn innovative-product franchise as a profitable funding engine for a pipeline that GSK and other sophisticated buyers have independently validated, with HS-20093 now moving closer to Chinese commercialization. Bears see a concentrated aumolertinib profit pool, unusually large licensing contributions, undisclosed royalty economics and a valuation that already assigns billions of dollars to clinical options whose global commercialization belongs to someone else. Both cases contain truth. The stock price is paying for more than the domestic business, and the central task is to decide how much option value is already prepaid.

Company vertical history and financial review

Hansoh's history is best understood as four stages rather than a chronology of announcements.

The first stage, from its origins in Lianyungang in 1995 through the mid-2010s, was an exercise in building a domestic branded-pharmaceutical machine. Company filings identify Zhong Huijuan as the founder and show that she has spent roughly three decades in China's pharmaceutical industry; contemporary profiles describe her earlier career as a chemistry teacher before moving into pharmaceutical management. Hansoh built franchises in oncology, CNS, anti-infectives and metabolic disease at a time when China's hospital market rewarded differentiated branded generics, manufacturing quality and physician access far more than globally novel chemistry.

That business model generated the financial resources for the second stage: moving from imitation to innovation. The transition began before the IPO rather than after it. By the time Hansoh came to Hong Kong in June 2019, it had already invested in novel compounds, but public-market investors still largely understood it as a highly profitable Chinese pharmaceutical manufacturer attempting to become an innovative company. The global offering comprised about 551.3m shares, the offer price reached HK$14.26, and the transaction raised around US$1bn. Pre-IPO shareholders included institutional investors such as Hillhouse and Boyu alongside founder-controlled Stellar Infinity and other large holders.

The IPO story mattered because it arrived just before China's pharmaceutical economics changed sharply. The old branded-generic formula was being compressed by volume-based procurement, while the regulatory system increasingly rewarded genuine clinical novelty. Hansoh had both carrot and stick. Aumolertinib, flumatinib, PEG-loxenatide and other innovative products gave it new growth sources; procurement pressure made remaining dependent on mature brands progressively less attractive. By 2021, innovative medicines already supplied RMB4.20bn, or 42.3% of revenue.

The third stage, 2021-2023, was the uncomfortable middle of the transition. Revenue fell from RMB9.94bn in 2021 to RMB9.38bn in 2022 even as innovative-product sales rose 19.1% to RMB5.01bn. The old base was shrinking faster than the new base could initially compensate. Mature-product sales in my reconstruction dropped about 22% in 2022 and another 25% in 2023. Yet the innovative mix crossed 50% in 2022, and recurring product sales stabilized in 2023. Financially, this was the point at which Hansoh showed that its innovation strategy could replace lost generic economics rather than merely coexist with them.

The strategic turn came in 2023 with GSK. Hansoh licensed HS-20089 in October and HS-20093 in December, converting internal ADC research into hard evidence that a global pharmaceutical company considered its molecules worthy of late-stage international investment. The upfront payments were modest relative to the multi-billion-dollar headline totals, but their signaling value was large. GSK paid US$85m for HS-20089 and US$185m for HS-20093, while accepting most of the future ex-Greater-China development and commercialization burden. Hansoh retained Greater China and a contractual path to milestones and royalties.

In hindsight, those deals genuinely changed the market's framework for the company. The old question was whether innovative products could offset generic erosion. The new question became whether Hansoh could repeatedly manufacture assets that Western pharma would finance globally. That question produced a fourth stage, from 2024 through the present, in which licensing became systematic rather than episodic.

Merck agreed in December 2024 to pay US$112m upfront for ex-China rights to oral GLP-1 candidate HS-10535, with up to US$1.9bn of contingent milestones and royalties. Regeneron followed in June 2025 with US$80m upfront and up to US$1.93bn of milestones for dual GLP-1/GIP agonist HS-20094, plus double-digit royalties. Roche licensed ex-Greater-China rights to CDH17 ADC HS-20110 in October 2025 for US$80m upfront and potential milestones. Glenmark then obtained aumolertinib rights across a broad group of emerging and developed markets in December 2025; the upfront was not disclosed, while cumulative regulatory and commercial milestones could exceed US$1bn. In July 2026, Avere/NextCure received ex-Greater-China rights to oral IL-23R peptide HS-20118 under economics that included up to US$120m of upfront payments, US$2.18bn in milestones and royalties.

USD translations use rounded HK$7.80/US$ on the research date solely for scale; contractual rights remain USD-denominated. Royalty tiers for most of these transactions are not disclosed publicly, which is a material valuation limitation.

The table shows why the “headline deal value” narrative needs discipline. For the two GSK deals, only US$270m of upfront consideration is confirmed as received: US$85m in 2023 and US$185m in 2024. The remaining US$3.01bn of stated GSK milestones is conditional. Hansoh's public disclosures through the research date do not identify a success-based GSK milestone as having been received. The positive HS-20093 trials raise the probability of future payments; they do not turn conditional consideration into an asset at face value.

This distinction also explains FY2025 better than the 30.4% “innovative medicines and collaborative products” growth headline. Collaboration revenue reached RMB2.12bn. The disclosed US$112m Merck, US$80m Regeneron and US$80m Roche upfronts total US$272m before considering the undisclosed Glenmark upfront. At normal 2025 exchange rates those three alone are of roughly the same order as reported collaboration revenue, making it unnecessary to assume a large hidden GSK milestone to explain the year. The accounting dates may not align perfectly with contract signing or cash receipt, so this is an inference rather than a revenue-recognition reconciliation.

The financial vertical confirms that the business has crossed the most difficult part of its transformation.

† Operating cash flow less total reported capital expenditure; it is not the owner-earnings measure used later because some capex is growth investment. Sources: Hansoh annual results.

Over the five years, cumulative operating cash flow was approximately RMB19.03bn against cumulative net profit of RMB18.50bn, a cash-conversion ratio of 1.03 times. That is unusually clean for a company simultaneously increasing R&D intensity from about 18% to more than 22% of revenue. It also means Hansoh does not have an accounting-earnings problem of the type that would force a wholesale rejection of P/E in favour of cash flow. The bigger issue is composition: the 2025 cash flow figure includes an unusually favorable period for licensing and collaboration receipts.

Capital intensity is low relative to earnings. Capex fell from RMB1.51bn in 2021, when the company was investing more heavily in facilities, to roughly RMB0.3–0.5bn annually from 2022 onward. In 2025 PP&E depreciation was RMB351m against RMB458m of total capex. Hansoh does not disclose a formal maintenance/growth split. For owner-earnings analysis I use RMB0.30bn as an approximate 2025 sustaining requirement and treat the remaining RMB0.16bn as expansion-related. That is an analytical assumption rather than a company figure.

On that basis, reported 2025 owner earnings are about RMB6.44bn: RMB6.74bn of operating cash flow less RMB0.30bn maintenance capex. Converted at the research-date exchange rate, the stock trades around 27 times those owner earnings, versus roughly 31 times accounting earnings. The difference is only about 13%, well below the report framework's 30% threshold that would make owner earnings the mandatory sole basis of valuation. Normalized recurring owner earnings are lower, however, because licensing cash inflates 2025 operating cash flow. Removing collaboration revenue mechanically would push recurring owner earnings closer to RMB4.3bn and the corresponding multiple toward 40 times. I therefore use SOTP rather than either headline number.

The balance sheet is almost anomalously liquid. At 2025 year-end Hansoh had RMB31.55bn of cash and bank balances: RMB2.94bn unrestricted cash, RMB0.47bn deposits under three months and RMB28.14bn time deposits longer than three months. Those longer deposits yielded 1.35%-4.50%. Bank interest contributed RMB1.08bn of 2025 other income. At 1 RMB = HK$1.1636, the cash balance was about HK$36.7bn, or HK$6.05 per share.

Yet this cash has to be analyzed together with financing. Hansoh placed 108m new shares in August 2025 at HK$36.30, a 6.5% discount to the previous close, raising about HK$3.90bn net. It then issued HK$4.68bn of zero-coupon convertible bonds due 2033, raising approximately HK$4.64bn net at an initial conversion price of HK$57.39. Management earmarked roughly 65% of bond proceeds for R&D and in-licensing, 25% for R&D/manufacturing infrastructure and 10% for working capital, with deployment extending to 2031.

The fresh convertible proceeds do not simply add HK$4.64bn to net cash because the bond is also debt. Pro forma gross liquidity rises, while net financial value changes little before issuance costs. Potential dilution is modest at about 1.3%, but the pattern matters. A company with more than RMB30bn in cash is continuing to raise external money. That only creates shareholder value if the incremental pipeline and in-licensed assets earn returns comfortably above the cost of the dilution and capital.

Shareholder distributions are respectable but not dominant. Hansoh declared HK$0.4316 per share for FY2025, roughly HK$2.62bn in aggregate at the current share count, equivalent to about RMB2.25bn and roughly 40% of FY2025 earnings using the research-date FX rate. The company did not repurchase shares in 2025. That leaves most internally generated cash available for R&D and business development.

ROE needs two readings. FY2025 profit of RMB5.56bn against year-end equity of about RMB35.36bn gives a simple ending-equity ROE of roughly 15.7%; using average equity lifts it into the high teens. Excluding average excess cash and stripping interest income produces a far higher operating return on the small amount of tangible capital actually needed to sell drugs. Depending on the treatment of pipeline R&D, normalized cash-adjusted operating returns can exceed 60%. That figure should not be treated as a conventional industrial ROIC: drug intellectual property is created through R&D that accounting standards expense rather than capitalize. The economically useful conclusion is narrower. Hansoh's commercial drug business is highly capital-light; the bloated cash balance is what depresses consolidated ROE.

Governance is where the history and balance sheet intersect. Zhong Huijuan is founder, chairlady and CEO, combining roles despite Hong Kong's corporate-governance provision favouring separation. The company explains the arrangement by her industry experience and decision-making role. Founder-controlled Stellar Infinity owns 3.9bn shares; against the latest 6.064bn-share denominator that is roughly 64.3%. Stellar sits beneath the Sunrise trust structure, in which Zhong has consent rights on key matters and her daughter, executive director Sun Yuan, is beneficiary.

The family relationship with Hengrui is unusually important for a peer comparison. Hengrui chairman Sun Piaoyang is Zhong Huijuan's spouse. This is not merely a press-profile curiosity: Hengrui's April 2026 HKEX filing explicitly treated Hansoh entities as connected persons because the spouse of Hengrui's chairman controls Hansoh, and Sun abstained from voting on a transaction involving transfer/novation of rights relating to KiOmed.

That structure creates both knowledge advantages and governance costs. Two of China's important pharmaceutical companies have controlling families connected by marriage while competing for oncology assets, clinicians, R&D talent and capital-market attention. Hansoh's own controlling shareholders are subject to a non-competition deed, but that does not erase a minority investor's need to watch related transactions and allocation of opportunities between two economically connected competing groups. I apply a modest governance discount in the valuation multiple rather than assuming that founder ownership is automatically perfect alignment.

Business model, industry and horizontal competition

Hansoh's real economic engine is now a self-funding loop between Chinese commercialization and drug discovery, but its moat differs by leg.

The domestic commercial franchise has channel strength, physician familiarity, manufacturing know-how and the ability to navigate NMPA approval and NRDL reimbursement. Those are real capabilities. They are not equivalent to permanent pricing power. China's reimbursement system deliberately uses national purchasing leverage to exchange lower prices for wider access, while the generic portion of Hansoh's old portfolio has already shown how quickly economics can deteriorate. The legacy sales bridge, falling from RMB5.51bn to RMB2.68bn in four years, is the clearest quantitative measure of that policy exposure.

The innovative franchise has a stronger moat because differentiation is molecule-specific. Aumolertinib's accumulating labels, clinical data and entrenched use in EGFR-mutated lung cancer create value that generic channel strength alone could never produce. Yet the moat is bounded by competing third-generation TKIs, reimbursement bargaining and patent duration. The same principle applies to flumatinib and other approved innovative products. Product innovation increases differentiation; it does not give Hansoh a monopoly on Chinese oncology.

The discovery platform is potentially the most valuable moat. GSK did not license one Hansoh ADC and disappear; it licensed two. Merck, Regeneron and Roche subsequently paid upfront cash for unrelated mechanisms and modalities. Repeat transactions across ADCs, small molecules and metabolic drugs are stronger evidence than a single blockbuster partnership because they reduce the probability that Hansoh simply got lucky with one compound.

Still, the repeat-deal record has only been tested for about three years. A mature biotech platform should eventually create royalties, milestone receipts, multiple launches and preferably a second generation of deals after the first assets have entered pivotal development. Hansoh has achieved the first half of that proof. HS-20093's 2026 Phase III successes move it closer to the second half.

Cost structure gives the company unusual operating leverage. Pharmaceutical manufacturing costs are low relative to selling price: 2025 cost of inventories sold was only about RMB1.13bn against RMB12.91bn of pharmaceutical-product sales, implying product gross margin near 91%. The large controllable costs are people, commercial expenditure and especially R&D. R&D reached RMB3.36bn, 22.3% of revenue. A licensing upfront drops through the income statement with much greater incremental margin than an additional RMB of product revenue, which is another reason reported margins can jump in licensing-heavy years.

Hansoh's industry is undergoing two opposite policy cycles at once. Domestically, centralized purchasing and NRDL negotiations keep compressing the economics of undifferentiated drugs. Internationally, Western pharma is becoming more willing to import Chinese innovation. Reuters reported US$137.7bn of Chinese outbound licensing headline value in 2025 and another record pace in 2026, driven partly by upcoming Western patent cliffs and the relative productivity of Chinese clinical development.

This is why the correct peer group needs two dimensions. Hengrui and Innovent show what a scaled Chinese innovative commercial company looks like. Kelun-Biotech shows what the market is willing to pay for a purer ADC licensing platform. BeOne Medicines shows the alternative path: retain more global commercial responsibility, absorb the corresponding cost and eventually generate global product sales at a scale far beyond Hansoh's direct overseas business.

Peer figures are not perfectly accounting-comparable. Hengrui's consolidated market capitalization is dominated by its A shares; its normalized P/E cited here is Morningstar's current measure. Innovent's 2026E P/E uses a published consensus EPS of RMB1.20 and the 2026-08-14 share price. Kelun's sales multiple is derived from its approximately HK$124bn market value and FY2025 revenue.

Hengrui is the closest operating comparator and also the most complicated governance comparator because of the Zhong-Sun family connection. It is more than twice Hansoh's revenue scale, has a broader innovative portfolio and now pursues licensing at industrial scale. Its July 2025 GSK transaction included US$500m upfront for HRS-9821 plus options on 11 additional programmes and up to US$12bn of potential milestones. Hengrui's premium multiple reflects scale and pipeline breadth, but it also means its valuation already assumes sustained innovative productivity.

Hansoh is financially cleaner than Hengrui in one respect: the cash pile relative to its own business is much larger. Hengrui is stronger in another: breadth. Aumolertinib matters so much to Hansoh that a single class-level competitive shock can move group earnings materially. Hengrui has more ways for success in one franchise to offset disappointment in another. That breadth deserves some premium independent of the family relationship.

Innovent is the more aggressive commercial-biotech comparison. FY2025 revenue reached RMB13.0bn, up 38.4%, and product revenue RMB11.9bn, up 44.6%. It has also moved decisively into mega-partnerships: Takeda agreed to a US$1.2bn upfront plus up to US$10.2bn of milestones in October 2025, while Lilly signed another agreement in February 2026 with US$350m upfront and up to US$8.5bn more contingent. Its valuation reflects faster growth and a market belief that its commercial organization can absorb additional products, illustrated by Lilly transferring China commercialization rights for Verzenio to Innovent in June 2026.

Compared with Innovent, Hansoh has much stronger current profitability and a much larger net-cash buffer. Innovent has a more biotechnology-like growth narrative and a higher valuation. The market is effectively asking Hansoh investors to pay less for each unit of near-term growth but to accept greater concentration in one domestic molecule and a less developed global commercial organization.

Kelun-Biotech is the clearest warning against choosing peers mechanically. Its FY2025 revenue was only RMB2.06bn and it lost RMB382m, yet its August 2026 market capitalization was approximately HK$124bn. At roughly 52 times sales, investors are pricing Kelun primarily as an ADC asset portfolio rather than an operating drug company. Its December 2025 licensing of SKB105 to Crescent followed the same basic model as Hansoh's deals: US$80m upfront, up to US$1.25bn milestones and ex-Greater-China rights.

If one used Kelun as Hansoh's primary multiple anchor, Hansoh would look extraordinarily cheap. That would be the wrong inference. Most of Hansoh's current enterprise value is still supported by existing Chinese drug earnings. The licensing platform should command option value, but valuing all of Hansoh at pure-play ADC sales multiples would capitalize the same pipeline twice: once in product earnings and again in biotechnology optionality.

BeOne is the opposite benchmark. In H1 2026 it generated US$3.17bn of net product revenue, up 31%, and in August raised 2026 total-revenue guidance to US$6.6–6.8bn with expected GAAP operating income of US$1.0–1.1bn. It is spending heavily on global commercialization and manufacturing, including a further US$300m expansion of its US manufacturing/R&D site in 2026.

BeOne illustrates what Hansoh gives up by out-licensing: the owner of a globally successful asset can capture product gross profit rather than a royalty percentage. It also illustrates what Hansoh avoids. Building clinical, regulatory, manufacturing and commercial organizations across North America and Europe requires years of investment and large fixed costs before scale economics become attractive.

I read Hansoh's licensing strategy as both a considered capital-allocation choice and evidence of a structural capability gap. The first part matters: Hansoh can transfer billions of dollars of global trial and launch obligations to companies with established infrastructure while retaining China and royalties. The second part matters equally: as of 2026 it does not possess BeOne's global commercial machine, so “retaining everything” would not have been a free alternative. The relevant counterfactual value of an asset is its global NPV minus the capital, dilution, execution risk and time required to build the organization needed to realize that NPV.

Hansoh is best valued as a domestic pharmaceutical franchise plus a portfolio of retained royalty and pipeline options, not as a single P/E stock. Its ecological niche is neither Hengrui-like fully diversified pharma nor Kelun-like pure biotechnology. It is a highly profitable Chinese commercial platform that has become unusually productive at manufacturing licensable assets.

Current fundamentals and pipeline

FY2025 delivered on almost every reported operating line. Revenue rose 22.6% to RMB15.03bn, profit rose 27.1% to RMB5.56bn, R&D rose 24.3% to RMB3.36bn and operating cash flow reached RMB6.74bn. Innovative medicines plus collaboration accounted for 82.2% of revenue, while oncology alone was 66.4%. Recurring product sales rose 20.8%, which is the number I consider more important than the reported top-line growth because it removes the largest licensing distortion.

The 82.2% figure should not be described as “82.2% innovative-product mix.” Pure innovative-product sales were closer to RMB10.24bn, approximately 68% of group revenue on my reconstruction. Collaboration was another 14%. Mature products supplied the remaining 18%. That is still a dramatic change from 2021, when innovative products were only 42.3% of sales, but the distinction matters for both growth and margins.

Hansoh's disclosed product economics also suggest little evidence of operational strain. Inventories were RMB609m at year-end, down from RMB651m; trade and bills receivable were RMB3.06bn versus RMB3.17bn. Those balances fell despite 22.6% revenue growth. Cash conversion accelerated rather than deteriorated. This is not the pattern of a company stuffing channels to create headline sales.

The catch is that Hong Kong's reporting cadence leaves investors unusually blind at this particular date. There is no Q1 2026 income statement and the H1 report is scheduled for board consideration on August 26. As a result, a literal “last four quarters” analysis cannot be constructed from company filings. The cleanest current picture remains FY2025 plus drug-development disclosures in 2026.

Those disclosures have been favourable. Aumolertinib received EU approval, adding to the UK authorization obtained in 2025. In China the label continued to broaden. HS-20093 then produced two pivotal positive readouts in July 2026, including overall survival in small-cell lung cancer and independent-review PFS in osteosarcoma. The latter is particularly valuable because Hansoh retains Chinese rights and intends to discuss a BLA with CDE.

For GSK, HS-20093's progress matters even more than its current accounting contribution. GSK acquired ex-Greater-China rights when the asset was much earlier. It subsequently took the programme into global development, and the asset received FDA Breakthrough Therapy and EMA PRIME designations. Each step improves the probability distribution around eventual royalties. None establishes peak sales, royalty percentages or final regulatory approval.

HS-20089 is less mature and therefore carries a wider valuation range. The B7-H4 target has attracted multiple global programmes, making target biology credible but competitive. Hansoh's economics depend on GSK deciding that efficacy, safety and differentiation justify continued spending. A licensing agreement transfers development cost; it does not transfer clinical risk away from Hansoh's shareholders because pipeline value falls if the partner terminates.

The metabolic pipeline broadens the option portfolio. Merck's HS-10535 oral GLP-1 deal and Regeneron's HS-20094 GLP-1/GIP deal show that Western demand for Hansoh's science extends beyond ADCs. That matters because ADC valuations are vulnerable to target crowding and class-specific safety events. A platform that can create credible oral metabolic and peptide assets is economically safer than a company whose entire licensing identity rests on one conjugation technology.

What the market is trading now is a mixture of real fundamentals and a broader theme. The fundamentals are recurring-product growth above 20%, positive aumolertinib label expansion, HS-20093 pivotal success and repeat upfront payments. The thematic layer is China's extraordinary rerating as a global source of pharmaceutical assets. Reuters' US$137.7bn 2025 licensing statistic makes clear why any company with a credible discovery engine has attracted capital.

Capital issuance has pushed in the opposite direction. The August 2025 equity placement at HK$36.30 diluted existing holders by roughly 1.8%, and the 2026 convertible could dilute another 1.3% if converted. The current HK$33.34 price is below both the placement price and the January 2026 pre-bond level. That suggests the market is no longer willing to value “more cash plus more pipeline spending” as an unambiguous positive.

The bull case rests on five connected pieces of evidence. First, recurring product sales rose 20.8%, so current growth survives removal of licensing. Second, mature-drug erosion has slowed to low single digits. Third, aumolertinib's indication set is expanding. Fourth, repeat Western counterparties validate Hansoh's discovery capability across modalities. Fifth, HS-20093 has moved from “interesting licensed ADC” toward a potential commercial asset after positive Phase III outcomes.

The bear case begins with concentration. The external RMB5.53bn aumolertinib sales estimate implies that one molecule may account for more than half of innovative-product revenue. The third-generation EGFR market is crowded, and Hansoh cannot defend economics solely through distribution once comparable molecules accumulate indications. A large price/share loss here would reach group profit much faster than a failed early-stage pipeline asset.

The second disagreement is about licensing quality. Bulls assign large present value to US$1bn-plus “deal values”. I assign value to upfronts, probability-adjusted milestones and royalties. The two are very different. Royalty tiers are not publicly disclosed, GSK milestones have not yet been disclosed as received, and development success probabilities remain below 100%. The more the stock rerates on total nominal milestones, the more fragile that rerating becomes.

The third disagreement is capital allocation. A bull can reasonably argue that an R&D platform with opportunities across ADCs, metabolic disease, immunology and peptides should maintain excess liquidity because attractive assets can appear suddenly. The bear can point to RMB31.5bn already earning bank-deposit returns while management issued both equity and convertible debt. The valuation should give management credit only after the newly raised capital begins producing clinical or licensing returns.

The fourth is whether internationalization should receive a premium today. EU approval of aumolertinib is real regulatory validation. Without a disclosed European commercial partner or global sales infrastructure, I assign little near-term revenue to it. A material European licensing agreement would change that conclusion quickly.

Valuation, risks and tracking indicators

Historical P/E is not the most reliable way to value Hansoh because the object being valued has changed. A 2019 multiple capitalized a mature branded-generic profit pool. A 2021 multiple capitalized an emerging innovative-drug story. A 2026 multiple capitalizes marketed innovations, a shrinking legacy tail, bank interest, recurring licensing opportunities and clinical royalties that do not yet exist. Comparing those multiples as if earnings quality were constant would create spurious precision.

At HK$33.34, FY2025 P/E is approximately 30.8 times using RMB0.93 EPS translated at 1 RMB = HK$1.1636. The FY2025 dividend yield is about 1.29%. Deducting RMB31.55bn of cash reduces enterprise value from roughly HK$202.2bn to HK$165.5bn. Yet after also removing the estimated after-tax bank-interest contribution from earnings, the ex-cash operating multiple remains around 31 times. The cash pile changes the balance-sheet risk dramatically but does little to make the normalized operating valuation cheap.

I cannot support a defensible exact historical valuation percentile without a verified daily multiple series. Qualitatively, today's multiple is below the 2020-2021 innovation-euphoria regime and above the policy-stressed 2022-2023 trough. I would describe it as around the middle-to-upper part of Hansoh's post-IPO valuation experience, rather than claiming a false “63rd percentile” or similar.

Relative valuation makes Hansoh look inexpensive, but that conclusion is dangerous. Hengrui's normalized P/E is above 40 times; Innovent's published 2026 consensus implies a forward multiple around the high 60s; Kelun trades at more than 50 times trailing revenue while loss-making. These comparisons prove that Chinese innovation assets carry large option premiums. They do not prove that those premiums are intrinsically justified.

Cash-flow passthrough is considerably better. Five-year cumulative operating cash flow of RMB19.03bn is 1.03 times cumulative net profit of RMB18.50bn. Using my RMB0.30bn estimate of 2025 maintenance capex gives reported owner earnings of about RMB6.44bn and a current owner-earnings yield near 3.7%. Using all 2025 capex gives free cash flow of RMB6.28bn, corresponding to a yield near 3.6%. Neither is a bargain yield for a drug company carrying real clinical and product-concentration risk.

What matters more is that the reported 2025 owner earnings include licensing receipts. A normalized recurring-product owner-earnings figure is substantially lower. For this reason I do not capitalize consolidated FY2025 earnings at one multiple. The absolute valuation below separates three economic assets: the domestic commercial franchise, the retained pipeline/licensing economics and net cash.

For the commercial franchise I start from normalized earnings rather than reported earnings. FY2025 net profit was RMB5.56bn. Bank interest contributes roughly RMB0.9bn after tax, and the RMB2.12bn collaboration line likely carried a very high incremental margin. Removing those items mechanically understates the commercial franchise because a meaningful portion of Hansoh's RMB3.36bn R&D spending belongs economically to the pipeline leg being valued separately. I therefore normalize commercial earnings at RMB3.8bn, RMB4.2bn and RMB4.8bn across scenarios after reallocating part of pipeline R&D. These are analytical assumptions, not reported segment profits.

For pipeline value I deliberately ignore nominal milestone totals. I assign RMB22bn, RMB45bn and RMB75bn of risk-adjusted value respectively to Hansoh's retained Chinese rights, milestone claims and royalty interests across the GSK, Merck, Regeneron, Roche and other programmes. The wide range reflects undisclosed royalty tiers and binary clinical outcomes. The optimistic figure is still far below the contractual headline sum of all possible milestones because probability and time value matter.

† Uses 1 RMB = HK$1.1636 as of 2026-08-14 and 6.06415bn shares. This is valuation-scenario analysis within a research framework, not investment advice.

The conservative case gives about HK$27 per share. It does not assume the pipeline is worthless; doing so would ignore several hundred million dollars of already-paid third-party validation. It does assume that investors eventually refuse to pay premium biotechnology multiples for domestic commercial earnings and apply a materially lower rNPV to future royalties.

The base case at HK$36.4 is only about 9% above the current price. That matters more than the apparent cheapness versus Innovent or Kelun. At today's quote an investor is already paying for a meaningful portion of the licensing platform. The stock can work from here, but the current valuation does not offer a large buffer against ordinary clinical disappointment.

The optimistic HK$49 valuation requires both legs to succeed. Domestic normalized earnings need to grow toward RMB4.8bn despite EGFR competition, and the market must be willing to capitalize those earnings at 31 times while simultaneously assigning RMB75bn of rNPV to pipeline and royalty claims. This scenario is plausible after the HS-20093 data, but it is not a conservative underwriting case.

The most fragile base-case assumption is the RMB45bn pipeline rNPV. Reducing it to 70% of my base estimate, or RMB31.5bn, cuts fair value from HK$36.4 to roughly HK$33.85. That is essentially the current stock price. Investors buying today have very little room for a broad clinical probability downgrade even if the domestic business continues to operate normally.

The margin-of-safety test is stricter still. Current HK$33.34 is about 23% above my conservative intrinsic value of HK$27.0. A price above conservative value has zero conservative-scenario margin of safety by definition.

If earnings remain flat for three years and the terminal earnings multiple is unchanged, the investor's principal expected return becomes the dividend yield, currently about 1.3% before any reinvestment return from retained earnings. China's 10-year government bond yielded 1.6937% on 2026-08-14 according to CFETS. Under the report framework's requested test, there is no margin of safety at this buy price.

Margin-of-safety sufficiency verdict: none.

That conclusion does not mean the company is overvalued under a normal base case. It means today's buyer is relying on growth and clinical execution rather than purchasing already demonstrated cash flows at a wide discount. This is a good-business/fair-price situation, not a traditional value setup.

The most serious business risk is aumolertinib concentration. I assign medium probability and high impact. An externally estimated RMB5.53bn of 2025 sales means even a 20% molecule-level decline could remove more than RMB1bn from revenue before considering operating leverage. The observable indicators are oncology-product growth, aumolertinib prescription/market-share data, competitor label expansions and NRDL pricing. The transmission path is direct: lower aum volume or price compresses commercial earnings and simultaneously reduces the multiple investors will pay for Hansoh's execution record.

HS-20093 and the wider ADC portfolio create the second risk. Probability is medium, impact high. Positive Phase III data lower risk but do not eliminate manufacturing, safety, regulatory and differentiation risk. A GSK delay, discontinuation, weak global pivotal result or regulator request for additional trials would reduce pipeline rNPV immediately, long before reported Hansoh revenue changes. Watch GSK's trial progression, regulatory submissions, Hansoh's Chinese BLA process and any disclosed milestone receipts.

The third is licensing-income normalization. Probability is high; impact on intrinsic value is only medium, while impact on reported growth and the stock narrative can be high. Collaboration revenue rose from RMB0.70bn in 2023 to RMB1.57bn in 2024 and RMB2.12bn in 2025. There is no economic reason it should grow smoothly each year. A period with few new upfronts could show flat or declining reported revenue even if underlying product sales remain healthy. The right indicator is recurring product growth, not consolidated growth.

Capital allocation is a medium-probability, medium-to-high-impact risk. Hansoh already held RMB31.5bn cash and then issued equity and a convertible bond. A successful in-licensing programme can justify that liquidity; a sequence of expensive assets that fail clinically would turn today's financial strength into tomorrow's sunk capital. The warning signs would be repeated financing while cash remains structurally high, R&D rising above about 30% of revenue without corresponding late-stage progress, or acquisitions large enough to alter the low-capital-intensity model.

The founder/family structure is a lower-probability but potentially high-impact governance risk. The April 2026 connected transaction between Hengrui and Hansoh entities shows that interactions can be real rather than theoretical. The observable indicator is the frequency and size of related transactions, especially transactions involving intellectual property, pipeline assets or manufacturing rights. The loss path is less likely to begin with accounting fraud than with minority investors becoming uncertain about which related company receives the best opportunity.

China policy risk has already fallen as a percentage of group value because mature products have shrunk to roughly 18% of revenue. It remains material for innovative drugs through NRDL negotiation. Aumolertinib's large reimbursed population makes volume access valuable, but the state remains a powerful price setter. The recurring product bridge suggests Hansoh can outrun this pressure at present; that conclusion changes if innovative growth falls into single digits while mature drugs resume double-digit decline.

The tracking dashboard should emphasize operating quality rather than news flow.

Sources for current/reference figures: Hansoh FY2025 results, July 2026 clinical announcements, external aumolertinib industry estimate and Hansoh's board-meeting notice.

The August 26 result has three numbers that matter more than consensus EPS: recurring pharmaceutical-product growth, the split between collaboration and product revenue, and oncology/aumolertinib momentum. A high reported top line driven primarily by a new upfront would be less bullish than a lower headline number with 20% product growth. The balance between the two is the fastest way to tell whether the market narrative is running ahead of the business.

Cross-synthesis, research uncertainties and sources

Vertically, Hansoh has proved one capability beyond reasonable dispute: it can adapt its product engine before the previous one disappears. The company entered public markets with much of its economics rooted in a Chinese branded-generic model. That model came under structural pricing pressure. Between 2021 and 2025, mature-product sales were approximately halved, yet total revenue grew from RMB9.94bn to RMB15.03bn and net profit more than doubled from RMB2.71bn to RMB5.56bn. That outcome required genuine replacement economics, not cosmetic reclassification.

The historical success was partly an era tailwind. China spent decades expanding hospital access and pharmaceutical consumption; companies with entrenched branded-generic portfolios could earn exceptional gross margins. Hansoh benefited. The resulting cash flow financed R&D just as Chinese regulation began rewarding innovative drugs more explicitly. The timing was fortunate, but management converted the opportunity into marketed medicines. Aumolertinib's multiple label expansions are evidence of product execution rather than industry beta.

Those old success factors are only partly durable. Hospital-channel strength and domestic regulatory experience remain useful. High generic pricing does not. The new determinants are clinical-science quality, trial execution, patent life, partner selection and capital allocation. Hansoh's repeat licensing transactions suggest that its R&D organization is competitive enough to satisfy sophisticated external diligence. The next proof point is economic conversion: approvals, milestones and royalties.

Horizontally, Hansoh's most important advantage over Hengrui is not scale; Hengrui is substantially larger. It is not pure pipeline optionality; Kelun offers more of that. It is the combination of a profitable domestic base, a giant net-cash position and a pipeline that Western pharma has repeatedly paid to access. Few Chinese peers have all three at the same time.

Its weakness is equally specific. Hansoh has not built the global commercial and regulatory machine that BeOne has built, so the majority of successful ex-Greater-China economics on licensed assets will accrue to partners. This is a rational trade while global capability is absent. The discount should remain until retained royalties and milestones become large enough that Hansoh can prove its capital-light model produces attractive lifetime economics rather than merely attractive upfront cash.

The market may currently be misjudging two things in opposite directions.

The first possible underestimation is the quality of recurring growth. Because the reported “innovative and collaborative” bucket contains licensing, skeptical investors can assume recent acceleration is largely financial engineering. The revenue bridge shows otherwise. Product sales alone rose 20.8% in 2025, innovative-product sales roughly 29.5%, and legacy erosion slowed substantially. The domestic operation is stronger than a headline reading of licensing revenue implies.

The possible overestimation is the monetizable value of licensing headlines. Hansoh's deals contain billions of dollars of nominal milestones, but GSK's two contracts have so far produced publicly confirmed upfronts of US$270m and no separately disclosed success-based milestone receipts. This gap between nominal transaction value and realized economics is exactly where biotechnology bull markets tend to overcapitalize optionality.

The stock at HK$33.34 sits between those two errors. My base SOTP is HK$36.4, only modestly higher than the market. The current price is not obviously excessive if aumolertinib remains resilient and the ADC portfolio progresses. It is also nowhere near a conservative purchase price, because a 30% haircut to the pipeline rNPV erases almost the entire valuation gap.

The one-year variables are unusually concrete. H1 2026 needs to prove product growth has not decelerated sharply. HS-20093's Chinese BLA path needs to advance. Investors need clarity on whether EU approval of aumolertinib can be turned into actual European economics. Collaboration income should be analyzed deal by deal, not extrapolated from 2025. The August 26 interim announcement will address the first of these within days.

At three years, the company will be judged on conversion. Aumolertinib cannot remain the overwhelming source of innovative-product economics forever. HS-20093 or another internally developed asset needs to become a second meaningful commercial franchise. GSK, Merck, Regeneron and Roche programmes need to generate milestones, royalties or both. If collaboration revenue in 2028 still consists mainly of ever-new upfront deals while earlier licensed assets have not matured, the “platform” multiple deserves to fall.

At five years, the question becomes organizational. Hansoh has accumulated enough cash and funding capacity to decide whether it remains fundamentally a China commercialization company that exports intellectual property or begins retaining more global rights. A successful capital-light royalty model could justify never building a full Western sales force. A pattern of licensing every high-quality ex-China asset irrespective of maturity would instead reveal a permanent inability to capture full global economics.

The company becomes a materially better investment under three simultaneous conditions: the stock trades close to or below the low-HK$20s; recurring product growth remains at least mid-teens; and the HS-20093/other licensing pipeline has not deteriorated. The quality of the enterprise does not need to improve dramatically for a lower price to create the necessary margin of safety.

The research judgment should be overturned positively if Hansoh begins receiving meaningful disclosed GSK milestone or royalty cash, establishes a credible European aumolertinib commercialization arrangement, and proves that non-aum innovative products can carry domestic growth. The judgment should be overturned negatively if aumolertinib sales enter sustained decline while HS-20093 loses clinical or regulatory momentum. Those two developments together would remove both legs of the current valuation.

Bull reasons.

• FY2025 recurring product sales grew 20.8% after excluding RMB2.12bn of collaboration revenue, proving that recent growth is not solely licensing-driven.
• Derived innovative-product sales reached approximately RMB10.24bn and grew roughly 29.5%, while the mature base declined only about 3.9% in 2025.
• HS-20093 delivered positive Phase III endpoints in both SCLC and osteosarcoma in July 2026 after receiving FDA Breakthrough Therapy and EMA PRIME support.
• GSK, Merck, Regeneron and Roche have each paid real upfront consideration for Hansoh-originated assets, supporting the thesis that R&D productivity extends beyond one molecule.
• RMB31.55bn of cash and bank balances sharply limit financial distress risk and provide funding for late-stage development and in-licensing.

Bear reasons.

• An external estimate puts 2025 aumolertinib sales at RMB5.53bn, equivalent to roughly 37% of group revenue; EGFR class competition reaches group earnings directly.
• The GSK contracts contain US$3.01bn of contingent milestones beyond upfronts, but no success-based milestone receipt was separately disclosed through the research date; nominal deal value overstates realized economics.
• The stock trades around 31 times FY2025 earnings, while my base SOTP is only about 9% above market; clinical option value is already material in the quote.
• Hansoh raised approximately HK$3.90bn of equity and HK$4.64bn of net convertible-bond proceeds despite ending 2025 with RMB31.55bn cash, increasing the burden on management to prove incremental capital returns.
• Founder control, the combined chair/CEO role and the controlling family's relationship with Hengrui justify a governance discount, particularly after an actual 2026 connected transaction between Hengrui and Hansoh entities.

Pre-mortem.

The first concrete halving script runs through aumolertinib. During 2027-2028, osimertinib, furmonertinib and additional EGFR regimens continue extending indications while reimbursement negotiations force another effective price reset. Aumolertinib revenue falls 20–25% from the externally estimated RMB5.53bn base and group oncology growth approaches zero. At the same time, GSK's HS-20093 global programme produces a safety or differentiation problem after Chinese approval, reducing expected milestones and royalties by 70%. Normalized domestic earnings fall toward RMB3.5bn, pipeline rNPV collapses, and the market applies an 18–20x multiple rather than around 30x. Adding remaining cash gives an equity value in roughly the high-teens to low-HK$20s, consistent with a 40–50% loss from today's price. The ingredients are class competition, specific molecule concentration and simultaneous pipeline-multiple compression, rather than generic “biotech volatility.”

The second script is slower. Hansoh spends a large portion of its RMB30bn-plus liquidity on in-licensing, R&D facilities and new programmes from 2026 through 2029, pushing R&D above 30% of sales. Earlier GSK, Merck and Regeneron assets produce few commercial milestones, while management continues to raise or preserve capital instead of returning excess cash. Revenue remains around current levels in real terms, cash falls by RMB10–15bn, and the market stops valuing Hansoh as an ADC platform. Even without a clinical catastrophe, moving from a 31x headline P/E toward 20x on stagnant earnings could produce a similar permanent-loss outcome. Management's stated long-dated use of new financing makes this a capital-allocation risk that can be tracked well before the share price reaches that point.

My final judgment is that Hansoh has successfully completed the most important part of its historical transformation. Innovative product sales now dominate recurring revenue, legacy erosion is manageable, cash generation is real, and the company's science has attracted an unusually credible set of external counterparties. The old description “Chinese high-margin generic manufacturer” is obsolete.

The current quote already recognizes much of that achievement. A market capitalization of about HK$202bn prices in ADC and other pipeline options well beyond the domestic franchise. My HK$36.4 base value offers only modest upside, while HK$27 conservative value sits materially below market. The asymmetry is ordinary rather than exceptional: shareholders can earn attractive returns if the pipeline converts, but today's buyer is not protected from a normal clinical-disappointment scenario.

I would rather own Hansoh after either the evidence improves or the price falls. At present, the domestic business deserves respect, the pipeline deserves a positive rNPV, and the cash deserves full balance-sheet credit. None deserves unlimited credit.

【Company-profile scores】

• Fundamental quality: high
• Growth: high
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Recurring product sales grew 20.8% in 2025, but HK$33.34 already capitalizes meaningful pipeline value beyond the domestic franchise.
• Ideal buy price: see dedicated line below.
• Acceptable hold price: HK$31.0–40.0, centred on the HK$36.4 base SOTP and within its requested ±15% fair-value discipline.
• Clearly overvalued price: HK$54.0 and above, more than 10% above the HK$49.0 optimistic intrinsic-value scenario.
• Current-price classification: acceptable hold.
• Whether to wait for a better price: yes. A new position becomes compelling around HK$19.0–21.5 provided recurring product growth remains above 15%, aumolertinib has not entered structural decline and HS-20093 remains clinically intact. The opportunity cost is missing a rerating if GSK/global regulatory milestones arrive before such a price occurs; with a base-case three-year annualized return of only about 4%, I regard that opportunity cost as acceptable.
• Target holding horizon: 3–5 years.
• Expected annualized return: about −5% conservative, +4% base and +15% optimistic over three years, including roughly HK$0.50 per share of assumed annual cash dividends and the respective scenario terminal values.
• Max-loss risk: roughly 40–50% if aumolertinib revenue declines around 20–25%, pipeline rNPV is cut about 70% and the normalized commercial multiple compresses toward 18–20x.
• Reassessment-trigger signals: recurring product growth below 10%; innovative-product growth below 15%; two consecutive reporting periods of oncology contraction; material delay/discontinuation of HS-20093; R&D above 30% of revenue without new late-stage successes; or another material external financing transaction while net liquidity remains above roughly RMB30bn.

【Ideal Buy Price】19.0–21.5 HKD Basis: this is 20%–30% below the approximately HK$27.0 conservative SOTP value, preserving the required margin of safety rather than treating conservative intrinsic value itself as a buying signal.

【Valuation Range】

• current: 33.34 (close as of 2026-08-14)
• bear (conservative · ideal buy zone): [19.0, 21.5]
• base (fair · acceptable hold zone): [31.0, 40.0]
• bull (optimistic · above the clearly-overvalued line): [54.0, 58.0]

Research uncertainties.

The first blind spot is timing. H1 2026 results are scheduled for board consideration on 2026-08-26, nine days after this research base date. Any material change in product growth, collaboration revenue, cash or expenses will immediately supersede the current-period analysis.

The second is aumolertinib disclosure. Hansoh does not publish molecule-level revenue or profit. The RMB5.53bn figure used to size concentration is an external industry estimate. I also could not verify from current primary material a sufficiently reliable nationwide 2026 prescription share, dose-adjusted NRDL price history versus osimertinib or complete patent-expiry schedule. Those are important omissions in a molecule that may produce 40–50% of normalized commercial earnings.

The third is royalty economics. Hansoh and its partners disclose “tiered royalties” but generally do not publish the percentages or exact thresholds. A conventional royalty assumption would create false precision. That is why pipeline rNPV spans RMB22bn-RMB75bn in the scenario analysis.

The fourth is cash geography. Hansoh discloses the structure and yield of bank deposits but not a sufficiently clean onshore/offshore breakdown in the extracted filings to model repatriation restrictions and currency availability precisely. I therefore value cash at face value, while retaining a governance/capital-allocation discount elsewhere.

The fifth is maintenance capex. Management does not split the RMB458m FY2025 capex between maintenance and growth. My RMB300m sustaining-capex estimate is based on depreciation, the recent capex run-rate and known expansion projects; changing that assumption by RMB100m has only a small effect on total valuation.

Primary and major secondary source ledger.

Hansoh's FY2025 annual-results announcement is the anchor source for revenue, profit, R&D, therapeutic-area mix, product development, balance sheet, financing and governance.

The underlying financial-note disclosures provide the crucial separation between RMB12.91bn product sales and RMB2.12bn collaboration revenue, as well as RMB1.08bn bank interest income, depreciation and balance-sheet items.

Hansoh's 2021-2024 annual results underpin the five-year product-revenue reconstruction, operating cash-flow history and innovation-mix transition.

Official GSK announcements and Hansoh disclosures provide the HS-20089 and HS-20093 deal economics, territorial carve-outs and development history.

Hansoh's July 2026 announcements provide the current HS-20093 Phase III evidence.

Hansoh's February 2026 disclosure and annual results provide the European aumolertinib approval; the exact regulatory approval date was 2026-02-12, with Hansoh announcing it on February 20.

Hansoh's financing announcements provide the August 2025 placement and 2026 convertible terms and intended use of proceeds.

HKEX is the source of the HK$33.34 close used throughout the valuation.

CFETS and market FX history provide the 2026-08-14 China 10-year government-bond yield and RMB/HKD translation rate used in the margin-of-safety and SOTP work.

Hengrui's HKEX filings establish the family-connected-person treatment, while Hengrui, Innovent, Kelun and BeOne disclosures provide the peer operating reference points.

Reuters is used primarily for the broader China out-licensing cycle and major peer licensing transactions rather than for Hansoh's own financial statements.

Other tickers mentioned

• 600276.SHG: Jiangsu Hengrui Pharmaceuticals, Hansoh's closest scaled domestic innovative-pharma comparator and a company controlled by the subject founder's spouse.
• 01276.HK: Hengrui's Hong Kong H-share listing, used for current Hong Kong price comparison after its 2025 dual listing.
• 01801.HK: Innovent Biologics, faster-growing Chinese commercial-biotech and mega-licensing comparator.
• 06990.HK: Kelun-Biotech, the clearest listed Chinese ADC/pipeline licensing-platform valuation comparison.
• ONC.US: BeOne Medicines, reference case for retaining and building large-scale global commercialization capability around Chinese-origin oncology assets.
• GSK.US: GSK, counterparty for HS-20089 and HS-20093 and the most important external validator and global developer of Hansoh's ADC portfolio.
• MRK.US: Merck & Co., licensee of Hansoh's oral GLP-1 candidate HS-10535.
• PFE.US: Pfizer, referenced as a global pharmaceutical valuation and licensing-market context company rather than a direct Hansoh operating peer.
• 4568.TSE: Daiichi Sankyo, global ADC benchmark whose integrated development economics provide context for what Hansoh relinquishes when it licenses ex-China rights.
• LEGN.US: Legend Biotech, conceptual reference for the partnership-based route to globalizing a Chinese-origin oncology asset; current market capitalization was about US$7.4bn in the latest market-data pull.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.